REGENTIS BIOMATERIALS Business Summary

Regentis Biomaterials Ltd. (RGNT) is a clinical-stage regenerative medicine company that generates revenue through the development and commercialization of its proprietary Gelrin hydrogel platform, primarily targeting the multi-billion dollar orthopedic tissue repair market. The company’s business model is centered on the production and sale of its lead product, GelrinC, a cell-free, off-the-shelf hydrogel implant designed to regenerate damaged articular knee cartilage. Following its December 2025 IPO on the NYSE American, Regentis is transitioning toward a commercial-stage entity, leveraging its CE Mark approval to secure strategic distribution partnerships in Europe while advancing a pivotal Phase III FDA clinical trial in the United States. Within the competitive landscape, Regentis operates alongside major orthopedic players such as Zimmer Biomet, Integra LifeSciences, and Orthofix Medical, distinguishing itself as a niche provider of restorative, minimally invasive solutions that avoid the complexities of cell-based therapies. The company’s leadership is anchored by Executive Chairman and CEO Dr. Ehud Geller, a prominent figure in the Israeli life sciences sector and Founder of Medica Venture Partners, who assumed the dual role in late 2025. In February 2026, the team was further strengthened by the appointment of Ori Gon as Chief Financial Officer and Chief Business Officer, bringing extensive capital markets and medtech experience from his previous roles at Tactile Mobility and ReWalk Robotics. The company’s core technology was pioneered by Co-Founder and Chief Scientific Officer Professor Dror Seliktar of the Technion - Israel Institute of Technology. The Board of Directors includes industry veterans such as Keith C. Valentine, CEO of SeaSpine, and Jeff Dykan of SCP Vitalife, reflecting a strong pedigree of institutional backing from investors including Medica Venture Partners and SCP Vitalife.